
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics is a clinical-stage biopharmaceutical company with a lead product candidate, oral (Z)-endoxifen, being evaluated for the treatment and prevention of breast cancer and other indications. While the company does not generate revenue yet, we believe that strong results or milestones from its various clinical trials over the next year could act as strong catalysts and drive the stock price. Furthermore, Atossa's proprietary form of Endoxifen shows potential in multiple settings and the recent appointment of a new CFO with extensive finance experience in global life-science businesses could benefit the company's financial management. However, there are risks to reaching a specific price target, including balance sheet/liquidity risks, failure of clinical trials, and competition.
Bears say
Atossa Therapeutics is facing multiple risks as they continue to conduct clinical trials for their lead product candidate, (Z)-endoxifen. These risks include potential balance sheet and liquidity issues, failure to gain regulatory approvals and suitable reimbursement, competition, and changing macroeconomic factors. Additionally, the company's current valuation may be attractive to some investors, but it is based on a NPV analysis and does not take into account the high risks associated with Atossa's operations. Overall, the company faces significant risks and their success in clinical trials, gaining regulatory approvals, and commercializing their products will be key factors in determining their future growth and potential upside for investors.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares